Welcome to our dedicated page for Bitwise MARA Option Income Strategy ETF news (Ticker: IMRA), a resource for investors and traders seeking the latest updates and insights on Bitwise MARA Option Income Strategy ETF stock.
Bitwise MARA Option Income Strategy ETF (IMRA) reports fund updates tied to monthly distributions for Bitwise's Option Income Strategy ETF suite. News for the fund centers on distribution per share, distribution rate, 30-day SEC yield, payment dates, return of capital treatment, expenses, and performance periods.
Fund updates also describe risks associated with the option-income approach, including derivative instruments, leverage, issuer-specific volatility, and differences between derivatives and direct holdings of traditional securities.
Imara Inc. announced positive final findings from its 93-patient Phase 2a clinical trial of IMR-687 for sickle cell disease (SCD), showing a 40% reduction in annualized vaso-occlusive crises (VOCs) compared to placebo. The study highlighted a significant increase in the time to first VOC (169 days vs 87 days) and improved patient-reported pain severity. Interim data from the open-label extension trial demonstrated sustained lower VOC rates and increased fetal hemoglobin (HbF) responses over eight months. IMR-687 was well-tolerated, paving the way for further trials, including the ongoing Ardent Phase 2b.
Imara Inc. (Nasdaq: IMRA) announces the presentation of final results from its 93-patient Phase 2a trial and interim data from the open-label extension trial for IMR-687, aimed at treating sickle cell disease. The results will be shared at the EHA Annual Congress from June 9-17, 2021. IMR-687 was shown to be well tolerated, with promising reductions in vaso-occlusive crises rates and increases in fetal hemoglobin levels. A conference call is scheduled for June 11, 2021, to discuss the findings further.
Imara Inc. (Nasdaq: IMRA) reported Q1 2021 financial results and highlighted progress in clinical trials for sickle cell disease and beta-thalassemia. The company completed enrollment for the transfusion-dependent arm of the Forte Phase 2b trial and opened higher dose arms for both Ardent and Forte trials. Cash reserves stand at $75.6 million. Q1 net loss was $10.3 million, down from $15.1 million a year ago. The firm expects R&D expenses between $50 million and $55 million for 2021. Interim analyses for the clinical trials are anticipated in H2 2021.
Imara Inc. (Nasdaq: IMRA) will host a conference call on May 11, 2021, at 8:30 a.m. ET to discuss its Q1 2021 financial results and recent business highlights. The call will be accessible through a live webcast on the company’s website. Imara is focused on developing therapies for rare genetic disorders affecting hemoglobin, with its lead candidate, IMR-687, targeting conditions such as sickle cell disease and beta-thalassemia. IMR-687 is a potent oral treatment designed to modify disease mechanisms.
Summary not available.
Imara Inc. (Nasdaq: IMRA) announced that independent data monitoring committees endorsed the opening of higher dose treatment arms for their IMR-687 clinical trials targeting sickle cell disease and beta-thalassemia. The higher dose arms were pre-specified in the trial protocols, allowing for doses of 300 mg or 400 mg based on patient weight. Initial dosing in the Phase 2a trial began as low as 50 mg daily. Preliminary data from these enhanced dosing arms is expected in the latter half of 2021, following recommendations from the safety review committee for dosage escalation in the ongoing Phase 2a trial.
Imara Inc. (Nasdaq: IMRA) announced significant advancements in the development of IMR-687, an oral treatment for sickle cell disease and beta-thalassemia. The company reported financial results for 2020, with a net loss of $49.2 million. IMR-687 is progressing through Phase 2b trials, with promising data from a Phase 2a trial indicating well-tolerated results and reduced vaso-occlusive crises. The company has raised $86.5 million in its IPO and expects research and development expenses between $50 million and $55 million in 2021. The leadership team has also expanded, enhancing operational capacity.
Imara Inc. (Nasdaq: IMRA) will host a conference call and webcast on March 5, 2021, at 8:30 a.m. ET to discuss its financial results for the year ended December 31, 2020. The call aims to provide insights into recent business developments and offers investors an opportunity to understand the company's progress. Imara is focused on developing IMR-687, a promising treatment for sickle cell disease and beta-thalassemia.
Imara Inc. (Nasdaq: IMRA) announced that CEO Rahul Ballal, Ph.D., will participate in a Fireside Chat at the SVB Leerink 10th Annual Global Healthcare Conference on February 26, 2021, from 1:40-2:10 p.m. ET. This clinical-stage biotechnology company focuses on developing therapeutics for rare inherited genetic disorders of hemoglobin, particularly with its investigational drug IMR-687. A replay of the chat will be available on Imara's website under the 'Events and Presentations' section.
Imara Inc. has appointed Kenneth Attie, M.D., as Senior Vice President and Chief Medical Officer. Dr. Attie brings over 30 years of experience in the biopharmaceutical industry, notably from Acceleron Pharma, where he led clinical development for therapies approved for rare anemias. His leadership is expected to enhance the development of IMR-687, a treatment targeting hemoglobin disorders. IMR-687 is designed to be a disease-modifying oral therapy for sickle cell disease and beta-thalassemia, potentially improving patient outcomes significantly.